Clinical Rheumatology

, Volume 29, Issue 3, pp 329–332 | Cite as

Mycophenolate mofetil in Takayasu’s arteritis

  • Ruchika Goel
  • Debashish DandaEmail author
  • John Mathew
  • Natasha Edwin
Brief Report


Mycophenolate mofetil (MMf) has recently been reported as a useful alternative immunosuppressive drug in autoimmune diseases. There is paucity of literature on its use in Takayasu's arteritis (TA). The aim of this study was to assess the safety and efficacy of MMf in Asian Indian patients with Takayasu's arteritis. Records of 21 consecutive patients with TA on treatment with oral MMF attending our centre from January 2005 to August 2008 were studied. The clinical, laboratory and angiography findings were noted and disease activity assessment was done using Indian Takayasu's arteritis activity score (ITAS) and physician's global observation score at baseline and last follow-up. Eleven patients were on steroids alone at baseline while ten patients had received azathioprine prior to administration of mycophenolate. The mean duration of follow-up on mycophenolate was 9.6 (±6.4) months. Nineteen patients (90%) received mycophenolate due to active disease, while in the other two patients, it was given to facilitate steroid tapering. Mycophenolate had to be discontinued in one patient due to skin rash. At the last visit, all the remaining 20 patients who continued mycophenolate had improvement in disease activity as evident by the drop in median ITAS [7 (range 0–19) versus 1 (range 0–7); p = 0.001]. A similar trend was noted in laboratory markers of inflammation with a reduction in mean Erythrocyte Sedimentation Rate (ESR) (68 ± 36.5 versus 43.2 ± 34 mm/first hour; p = 0.003) and mean C - Reactive protein (CRP) (31 ± 46.7 versus 17.3 ± 23.9 mg/L; p = 1.00). All patients received concomitant steroids, but there was a significant decrease in steroid dosage from 36 (±16) mg/day at baseline to 19 (±14) mg/day at last follow-up (p < 0.001). This study is the largest series till date establishing the use of mycophenolate as a safe and effective steroid-sparing immunosuppressant in Takayasu's arteritis.


India ITAS MMf Mycophenolate Takayasu’s arteritis 



Dr Ruchika Goel: none

Dr Debashish Danda: none

Dr John Mathew: none

Dr Natasha Edwin: none


  1. 1.
    Nakao K, Ikeda M, Kimata S, Niitani H, Niyahara M (1967) Takayasu's arteritis. Clinical report of eighty-four cases and immunological studies of seven cases. Circulation 35:1141–1155PubMedGoogle Scholar
  2. 2.
    Ishikawa K (1988) Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu's arteriopathy. J Am Col Cardiol 12:964–972CrossRefGoogle Scholar
  3. 3.
    Zheng DY, Liu LS, Fan DJ (1990) Clinical studies in 500 patients with aortoarteritis. Chin Med J (Engl) 103:536–540Google Scholar
  4. 4.
    Subramanyan R, Joy J, Balakrishnan KG (1989) Natural history of aortoarteritis (Takayasu's disease). Circulation 80:429–437PubMedGoogle Scholar
  5. 5.
    Sen P (1973) A monograph based on a study of 101 cases. Tata McGraw Hill, BombayGoogle Scholar
  6. 6.
    Conference on comparative studies of Takayasu's arteritis among Asian countries (1992) Tokyo, Japan, 16 to 17 May 1991. Heart Vessels Suppl 7:1–178Google Scholar
  7. 7.
    Hotchi M (1992) Pathological studies on Takayasu's arteritis. Heart Vessels Suppl 37:11–17CrossRefGoogle Scholar
  8. 8.
    Sivakumar MR, Misra RN, Bacon PA (2005) The Indian perspective of Takayasu's arteritis and development of a disease extent index (DEI.TAK) to assess Takayasu's arteritis. Rheumatol 44(Suppl):iii6–iii7CrossRefGoogle Scholar
  9. 9.
    Mishra R, Danda D, Jayaseelan L, Sivakumar R, Lawrence A, Bacon PA (2008) ITAS & DEI.TAK—scores for clinical disease activity and damage extent in Takayasu's aortoarteritis (TA). Rheumatology (Oxford) 47.ii:101Google Scholar
  10. 10.
    Danda D, Misra R, Jayaseelan L, Sivakumar R, Lawrence A, Bacon PA (2008) ITAS score for disease activity in Takayasu's aorto-arteritis (TA). Ann Rheum Dis 67(Suppl II):222Google Scholar
  11. 11.
    Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu's arteritis with methotrexate. Arthritis Rheum 37:578–582CrossRefPubMedGoogle Scholar
  12. 12.
    Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M et al (1994) Takayasu's arteritis. Ann Intern Med 120:919–929PubMedGoogle Scholar
  13. 13.
    Hu W, Liu C, Xie H, Chen H, Liu Z, Li L (2008) Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephron Dial Transplant 23(4):1307–1312CrossRefGoogle Scholar
  14. 14.
    Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M (2007) Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu's arteritis. Clin Rheumatol 26(11):1871–1875CrossRefPubMedGoogle Scholar
  15. 15.
    Daina E, Schieppati A, Remuzzi G (1999) Mycophenolate mofetil for the treatment of Takayasu's arteritis. Report of three cases. Ann Intern Med 130:422–426PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2009

Authors and Affiliations

  • Ruchika Goel
    • 1
  • Debashish Danda
    • 1
    Email author
  • John Mathew
    • 1
  • Natasha Edwin
    • 2
  1. 1.Department of Clinical Immunology and RheumatologyChristian Medical CollegeVelloreIndia
  2. 2.Department of General MedicineChristian Medical CollegeVelloreIndia

Personalised recommendations